Roth MKM tells investors in a research note that Tenax Therapeutics has secured global development, commercial, and patent rights to both oral and subcutaneous formulations of levosimendan to treat pulmonary arterial hypertension and heart failure with preserved ejection fraction, for which one of two pivotal trials has just started, expanding the company’s levosimendan rights beyond the U.S. and Canada. The firm, which made no change to its Buy rating or $30 price target, says the renegotiation allows Tenax to pursue a developmental and/or commercial partner for levosimendan, and views the changes as ultimately favorable for the company.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TENX:
- Tenax Therapeutics Amends Global Rights Deal with Orion
- Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan
- Tenax Therapeutics Raises $9M in Public Offering and Warrants
- Biotech Alert: Searches spiking for these stocks today
- Tenax Therapeutics prices 1.6M shares at $5.65 in public offering